【課題】三価の二重特異性抗体、それらの製造方法、前述の抗体を含む医薬組成物、及びその使用の提供。 【解決手段】本発明の三価の二重特異性抗体は、第1の抗原に特異的に結合し、且つ、2つの抗体重鎖と2つの抗体軽鎖から成る全長抗体、並びに前記重鎖のうちの一方のC末端に融合しているVHドメイン、及び前記重鎖のうちのもう片方のC末端に融合しているVLドメインを含んでなり、ここで、前記VHドメインと前記VLドメインが一緒になって第2の抗原に特異的に結合する抗原結合部位を形成する。 【選択図】図3
PROBLEM TO BE SOLVED: To provide trivalent, bispecific antibodies, methods for their production, pharmaceutical compositions containing the antibodies, and uses thereof.SOLUTION: The trivalent, bispecific antibodies of the invention comprise a full length antibody specifically binding to a first antigen and consisting of two antibody heavy chains and two antibody light chains and a VH domain fused to the C-terminus of one of the heavy chains and a VL domain fused to the C-terminus of the other of the heavy chains, wherein the VH domain and the VL domain together form an antigen-binding site specifically binding to a second antigen.




Download Full PDF Version (Non-Commercial Use)

Patent Citations (4)

    Publication numberPublication dateAssigneeTitle
    WO-2004032960-A1April 22, 2004Merck Patent GmbhPharmaceutical compositions directed to erb-b1 receptors
    WO-2004072117-A2August 26, 2004Pharmacia CorporationAnticorps contre c-met dans le traitement de cancers
    WO-2008100624-A2August 21, 2008Merrimack Pharmaceuticals, Inc.Antibodies against erbb3 and uses thereof
    WO-2009018386-A1February 05, 2009Medimmune, LlcProtéines de liaison à épitope multispécifiques et leurs utilisations

NO-Patent Citations (2)

    JPN6013033417; Gold D V et al: Cancer Research Vol.68,No.12, 2008, p4819-4826,2008
    JPN6013033418; Shen J et al: Journal of Immunological Methods Vol.318, 2007, p.65-74,2007

Cited By (0)

    Publication numberPublication dateAssigneeTitle